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Abstract. Cyclooxygenase (COX)-2 expression is positively 
correlated with malignant features in canine mammary 
carcinomas. Non‑steroidal anti‑inflammatory drugs (NSAIDs) 
inhibit COX activity and may therefore possess anticancer 
effects. Meloxicam is an NSAID that is widely used in human 
and veterinary medicine. High concentrations of meloxicam 
have been reported to be antitumorigenic in vitro; however, 
the effect of meloxicam at concentrations that are equivalent 
to those that can be obtained in vivo remains unknown. In 
the current study, the in vitro effects of low-dose meloxicam 
(0.25 µg/ml) on CF41.Mg canine mammary carcinoma cells 
were evaluated. The effects on cell proliferation, apoptosis, 
cell migration and invasion, in addition to the expression of 
different molecules associated with tumor invasiveness were 
analyzed. No effect on cell viability and apoptosis were 
observed. However, cell migration and invasion were signifi-
cantly reduced following treatment with meloxicam. MMP-2 
expression and activity were similarly reduced, explaining the 
impaired cell invasion. In addition, β-catenin expression was 
downregulated, while its phosphorylation increased. These 
results indicate that 0.25 µg/ml meloxicam reduces cell migra-
tion and invasion, in part through modulating MMP-2 and 
β‑catenin expression. Additional studies are required to eluci-
date the mechanism associated with the anti-invasive effect of 
meloxicam on CF41.Mg cells. The results of the present study 
suggest that meloxicam has a potential adjunctive therapeutic 
application, which could be useful in controlling the invasion 
and metastasis of canine mammary carcinomas.
Introduction
Mammary tumors are the most common malignancy in repro-
ductively intact female dogs (1). Malignant neoplasms represent 
~50% of total mammary tumors in canines, and ~50% of these 
have already metastasized at the time of clinical diagnosis (2). 
The enzyme cyclooxygenase (COX) controls the synthesis of 
prostaglandins (PG) from arachidonic acid (3). COX-2, an 
inducible form of COX, has been associated with carcinogen-
esis, cell proliferation, resistance to apoptosis, tumor tissue 
invasion, immunosuppression and angiogenesis (4,5). Several 
previous studies have suggested an association between COX-2 
expression and the progression of various human (6,7) and 
canine (8,9) types of cancer. In addition, high COX‑2 expres-
sion has been documented in canine mammary carcinoma and 
associated with tumor malignancy (10,11). There is known to 
be an association between cancer cell invasiveness, COX-2 
expression and matrix metalloproteinase (MMP) activity (12). 
COX-2 induces MMP-2 expression in breast cancer cells, 
facilitating tumor motility (13). MMP-2 expression has been 
associated with invasive carcinomas, given that it degrades 
type IV collagen (14).
Other molecular signaling cascades, including the 
Wnt/β-catenin signaling pathway, exert effects on cell survival, 
polarity and migration. In the Wnt/β-catenin signaling pathway 
binding of Wnt ligands to Frizzled receptors induces the 
release of β-catenin from a ubiquitinated cytoplasm complex, 
enhancing the translocation of β-catenin to the nucleus where 
it functions as a transcription factor (15). Numerous genes are 
targeted via β-catenin, which regulates tumor promotion and 
progression (15,16). An association between COX‑2/PGE2 
and the Wnt/β-catenin signaling pathway has been proposed 
in human breast cancer, where COX-2 expression is associ-
ated with increased β-catenin activity, promoting replicative 
immortality, invasion and metastasis (6).
Non‑steroidal anti‑inflammatory drugs (NSAIDs) inhibit 
COX activity, thus modulating PGE2 synthesis (17,18). Since 
COX-2 serves a role in tumor progression, there is consider-
able evidence that NSAIDs may serve a role in inhibiting 
this process in mammary tissue (19,20). Various NSAIDs, 
including piroxicam and meloxicam, have been studied in 
cancer. However, the preferential activity of meloxicam against 
COX-2 makes it an attractive therapeutic option compared 
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with non‑selective NSAIDs, because it may reduce side 
effects (21). Meloxicam is licensed for medium to long-term 
pain management in dogs, in which it induces only minor 
secondary effects (22). Few in vitro studies have determined 
the antiproliferative effect of meloxicam on mammary tumor 
cells, and they used high drug concentrations that cannot be 
translated in vivo (23,24).
Therefore, the novel analysis of lower concentrations 
of meloxicam is required. CF41.Mg is a canine mammary 
carcinoma cell line expressing mesenchymal-associated 
genes, including vimentin and N-cadherin, and low levels of 
E-cadherin (25), indicating that these cells exhibit invasive-
ness and may be representative of high histological grade 
canine mammary tumors. The aim of the present study was to 
analyze the potential antiproliferative and anti-invasive effects 
of meloxicam on CF41.Mg canine mammary carcinoma cells.
Materials and methods
Cell culture. The CF41.Mg (ATCC® CRL-6232™) cell line 
was purchased from the American Type Culture Collection 
(Manassas, VA, USA) and grown in Dulbecco's modified 
Eagle medium High Glucose (Hyclone; GE Healthcare Life 
Sciences, Logan, UT, USA), 10% fetal bovine serum (FBS) 
(Hyclone; GE Healthcare Life Sciences), 100 U/ml penicillin G, 
100 µg/ml streptomycin sulfate and 2 mM L-glutamine. The 
Madin‑Darby Canine Kidney (MDCK) cell line was provided 
by Dr Victor Neira (Laboratory of Animal Virology, University 
of Chile, Santiago, Chile) and cultured in minimal essential 
medium (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, 
USA), 10% FBS, 100 U/ml penicillin G and 100 µg/ml strep-
tomycin sulfate. All cultures were maintained in a humidified 
atmosphere with 5% CO2 at 37˚C. Evaluation of the growth 
kinetics of the cell lines under standard culture conditions was 
performed prior to starting the experiments.
Drug preparation. Meloxicam (Selleck Chemicals, Houston, 
TX, USA) and doxorubicin (Sigma‑Aldrich; Merck KGaA, 
Darmstadt, Germany) were prepared in dimethyl sulfoxide 
(DMSO; 40 mg/ml) and PBS (1 mg/ml), respectively. 
Concentrations ranges were chosen on the basis of the 
average and maximum serum drug concentrations previously 
reported in dogs (26,27). The final concentration of DMSO 
in the culture medium was 0.1% in all the experiments where 
meloxicam was used.
Indirect immunofluorescence. CF41.Mg and MDCK cells 
(1x104/well) were seeded and grown on sterile glass coverslips, 
and then fixed with absolute methanol. Cells were washed and 
blocked with PBS plus 2% bovine serum albumin (Applichem 
GmbH, Darmstadt, Germany) for 30 min in a humidified 
chamber at room temperature. Subsequently, the cells were 
incubated with rabbit anti-COX-2 primary antibody clone 
SP21 (MA5‑145; 1:50; Thermo Fisher Scientific, Inc.) at room 
temperature for 1 h as previously described (28,29). Cells were 
then incubated with a goat anti‑rabbit Alexa Fluor® 488 secary 
antibody (1:500; Invitrogen; Thermo Fisher Scientific, 
Inc.; A11008) for 1 h at room temperature. Coverslips were 
mounted using Vectashield® mounting media with DAPI 
(Vector Laboratories, Inc., Burlingame, CA, USA). Finally, the 
samples were analyzed with an epifluorescence microscope 
fitted with a color charge‑coupled device camera.
Western blot. Cells (2.5x105/100 mm dish) were seeded and 
exposed to 0.25 µg/ml meloxicam for 24-48 h and then lysed 
in RIPA Buffer with a Protease Inhibitor Cocktail added 
(both Cell Signaling Technology, Inc., Danvers, MA, USA), 
scraped and sonicated (3 cycles of 5 sec setting 10 of Branson 
sonifier 150; Danbury, CT, USA). After measuring protein 
concentration (Micro BCA Protein Assay kit, Thermo Fisher 
Scientific, Inc.), according to the manufacturer's indications, 
proteins (30 µg protein/lane) were resolved on 10% gels using 
SDS‑PAGE. Proteins were then transferred onto polyvinyli-
dene difluoride membranes, which were incubated overnight 
at 4˚C with primary antibodies directed against the following 
proteins: COX‑2 (1:200; Thermo Fisher Scientific, Inc.; 
MA5‑145), β‑catenin (1:1,000; BD Biosciences, Franklin Lakes, 
NJ, USA; 610154), phosphorylated (p)‑β-catenin (1:1,000; 
Cell Signaling Technology, Inc.; 9561) and MMP‑2 (1:1,000; 
Invitrogen; Thermo Fisher Scientific, Inc.; 35‑130-0Z). After 
washing, the membranes were incubated with anti‑rabbit IgG 
F (ab')2 fragment (A6667) and anti‑mouse IgG (Fab specific; 
A9917) peroxidase antibodies (1:5,000; Sigma‑Aldrich; Merck 
KGaA) for 1 h at room temperature. Protein bands were by 
enhanced chemiluminescence (Pierce ECL Western Blotting 
substrate; Thermo Fisher Scientific, Inc.; 32106). Relative 
levels of protein were determined by reprobing the membranes 
with anti-β‑actin antibody (1:1,000; Abcam, Cambridge, UK; 
ab8226) for 1 h at room temperature. The bands obtained 
were analyzed with ImageJ software version 1.49v (National 
Institutes of Health, Bethesda, MD, USA).
Cell viability assay. CF41.Mg and MDCK cells were seeded 
at a density of 1.5x103 cells/well into 96-well plates, cultured 
for 24 h and then exposed to 0-25 µg/ml meloxicam alone or in 
combination with doxorubicin, a chemotherapy drug frequently 
used as an adjuvant treatment in dogs with mammary carci-
noma. To evaluate synergism and sensitization, doxorubicin 
was added at the same time and after 24 h, respectively. MDCK 
cells were exposed only to meloxicam as a non-tumor negative 
control. Control groups were cultured without meloxicam and 
doxorubicin, but the corresponding amount of DMSO was 
added to the medium. Following an incubation period of 24 
and 48 h, cell growth was measured using the MTS assay 
(CellTiter 96® AQueous One Solution Cell Proliferation assay 
system; Promega Corporation, Madison, WI, USA), according 
to the manufacturer's instructions, with the absorbance at 
490 nm determined using a microplate reader. Each experi-
ment was performed 3 times in triplicate.
Flow cytometric apoptosis assay. CF41.Mg cells were 
cultured at a density of 4.5x105 per 100 cm2 dish. Cells treated 
with 0.25 µg/ml meloxicam or 500 ng/ml doxorubicin for 24 h 
were harvested with 0.25% trypsin‑EDTA, washed and resus-
pended with PBS plus 2% FBS. A FITC Annexin V Apoptosis 
Detection kit II (556419) was used according to the manufac-
turer's protocol (BD‑Pharmingen, San Diego, CA, USA), to 
identify cells in the early phases of apoptosis. Early apoptotic 
cells were defined as propidium iodide (PI)-/Annexin V+ and 
late apoptotic cells were defined as PI+/Annexin V+ (30). Cell 
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staining was measured using a FACSCalibur™ flow cytom-
eter and the data was analyzed with FACSDiva™ software 
version 6.1.3 (both BD Biosciences). Experiments were run in 
triplicate and ~10,000-20,000 events were analyzed.
Cell migration assay. A scratch wound healing assay was 
performed to determine cell migration ability. CF41.Mg 
cells were seeded at a density of 1x104 cells/well into 24-well 
plate and cultured until 80% confluent. Cell monolayers were 
scratched in a single line using a 200 µl pipette tip, rinsed with 
PBS to remove cell debris and allowed to heal for 24 and 48 h 
at 37˚C in the presence or absence of 0.25 µg/ml meloxicam. 
The average extent of wound closure was evaluated at 0, 24 
and 48 h by measuring the width of the wound, and images 
were captured using an inverted microscope. The migration 
area was calculated with ImageJ software version 1.49v 
using the following formula: Migration area=(area of original 
wound-area of wound after healing)/area of original wound.
Matrigel cell invasion assay. Cell invasion was assayed using 
Transwell® 24-well cell culture containing inserts with an 
8 µm pore size (BD Biosciences) coated with Matrigel. A 
total of 2.5x104 CF41. Mg cells were seeded into the upper 
chamber and incubated for 48 h in the presence of 0.25 µg/ml 
meloxicam and no FBS as previously described (20) against 
a gradient of 5% FBS in the lower chamber. Non‑invading 
cells on the upper side were wiped away with a cotton swab 
and the membrane was fixed with cold methanol (‑20˚C) for 
20 min. DAPI was used to stain the invading cells, which were 
examined by epifluorescence microscopy, with 5 microscopic 
fields examined per insert.
Gelatin zymography. MMP-2 and -9 release was detected using 
gelatin zymography. After cells were exposed to meloxicam, 
the culture medium was removed, mixed with sample buffer 
(0.125 M Tris‑HCl, pH 6.8, 10% SDS, 8% sucrose and 0.05% 
bromophenol blue) for 30 min at 25˚C. An electrophoretic run 
was then performed in a polyacrylamide gel copolymerized 
with 0.1% gelatin. Subsequently, the gels were washed with 
2.5% Triton X‑100 and incubated for 18 h at 37˚C in a buffer 
containing 50 mM Tris pH 7.4, 5 mM CaCl2 and 0.5 mM 
NaN3. Finally, the gels were stained with Coomassie blue and 
examined.
ELISA detection of PGE2. CF41.Mg cells (2x104/well) were 
incubated in 24‑well plates at 37˚C until 70% of confluence 
was reached. The culture medium was then changed and 
0.25 µg/ml meloxicam was added. After 24 and 48 h incuba-
tion, supernatants were removed and centrifuged at 1,000 x g 
for 10 min. The amount of PGE2 was determined using the 
Prostaglandin E2 ELISA kit‑Monoclonal from Cayman 
Chemical Company (Ann Arbor, MI, USA) according the 
manufacturer's protocol as previously described (31).
Statistical analysis. One way analysis of the variance 
for the cell viability assays, a Student's t test for the cell 
invasion, western blotting and annexin assays, and the 
Mann‑Whitney U test for the scrath plate assays were used 
to determine statistical significance between samples and 
their respective controls. P<0.05 was considered to indicate 
a statistically significant difference. Data were analyzed 
with SPSS software (version 22; IBM SPSS, Armonk, NY, 
USA).
Figure 1. Expression of COX‑2 in MDCK and CF41.Mg cells. (A) Representative immunofluorescence images of the (left panel) negative control, where the 
nuclei were visualized by DAPI, and COX‑2 expression in MDCK and CF41.Mg cells respectively (central and right panel). Scale bar, 32 µm. (B) Representative 
Western blot of the expression of COX‑2 in cell lysates, demonstrating a band at 72 kDa in both cell lines. Results are representative of 3 independent experi-
ments. COX, cycloooxgenase; MDCK, Madin‑Darby Canine Kidney.
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Results
COX‑2 is expressed in MDCK and CF41.Mg cells. MDCK 
and CF41.Mg cells were identified to exhibit COX‑2 expres-
sion through immunofluorescence (Fig. 1A) and western 
blotting (Fig. 1B). COX‑2 was localized in the cytoplasm of 
CF41.Mg cells and cytoplasm and perinucleus in MDCK cells 
(Fig. 1A). Western blot confirmed these results by revealing a 
band indicating COX‑2 at 72 kDa. No notable differences in 
the relative expression of COX‑2 between MDCK and CF41.
Mg cells were observed (Fig. 1B). The growth kinetics of 
MDCK and CF41.Mg cells without drug treatment (exhibited 
an increase in total cell number of ~3-fold over a 48 h period 
(data not shown).
Meloxicam does not inhibit CF41.Mg cell viability. Since 
meloxicam is known to inhibit COX+ tumor cells, its potential 
antineoplastic effect on CF41.Mg cells was examined using 
a cell viability assay. Meloxicam (0.25-25 µg/ml) did not 
decrease cell viability after 24 (100 vs. 96.33% viability in the 
control and 25 µg/ml meloxicam-treated cells, respectively) or 
48 h (100 vs. 90.29% viability in the control and 25 µg/ml 
meloxicam-treated cells, respectively) of exposure (Fig. 2A). In 
order to evaluate the potential cytotoxic effects of meloxicam 
on COX+ epithelial untransformed cells, the same assays were 
performed on MDCK cells. Similarly to in the tumor cells, 
meloxicam did not inhibit viability in MDCK cells (Fig. 2B).
Meloxicam does not have a synergistic effect with doxoru‑
bicin in CF41.Mg cells. To determine whether meloxicam 
could exert a synergistic effect with doxorubicin, the viability 
of CF41.Mg cells cultured in the presence of meloxicam and 
doxorubicin was examined. The viability of cells treated with 
meloxicam and doxorubicin was not significantly different 
compared with cells treated with doxorubicin alone (73.44 
vs. 51.60% viability in cells exposed to doxorubicin alone at 
24 and 48 h, respectively; 69.18 vs. 46.56% viability in cells 
exposed to doxorubicin and 25 µg/ml meloxicam at 24 and 
48 h, respectively; Fig. 2C).
Meloxicam is not associated with chemosensitization in 
CF41.Mg cells. To determine whether chemosensitization was 
associated with meloxicam, meloxicam was administered 24 h 
prior to doxorubicin. No significant difference in cell viability 
was found using this method (84.45 vs. 56.53% viability in 
cells exposed to doxorubicin alone at 24 and 48 h, respectively; 
82.13 and 47.15% viability in cells exposed to doxorubicin and 
25 µg/ml meloxicam at 24 and 48 h, respectively; Fig. 2D). 
The following experiments were performed using the lower 
meloxicam concentration (0.25 µg/ml), in order to mimic the 
plasma concentration typically observed in dogs receiving oral 
meloxicam at therapeutic doses (26).
Meloxicam does not affect CF41.Mg cell apoptosis. The 
incubation of CF41.Mg cells in the presence of 0.25 µg/ml 
meloxicam did significantly not affect early and late apoptotic 
cell numbers after 24 h compared with the control group 
(Fig. 3).
Meloxicam decreases CF41.Mg cell migration and invasion. 
The migratory ability of CF41.Mg cells was analyzed 
following exposure to meloxicam. Cells exposed to 0.25 µg/ml 
meloxicam were significantly less migratory compared with 
the control cells at 24 (P=0.001) and 48 (P=0.002) h in the 
wound healing assay, as indicated by a higher migration area 
(Fig. 4). Exposure to 0.25 µg/ml meloxicam also impaired the 
invasiveness of CF41.Mg cells in a Matrigel invasion assay. 
The number of invasive meloxicam-treated (0.25 µg/ml) cells 
was significantly lower compared with that of the control cells 
(P=0.025; Fig. 5).
Meloxicam decreases MMP‑2 expression in CF41.Mg 
cells. Based on the observed reduction in cell migration 
and invasion induced by meloxicam, the expression of 
Figure 2. Cell viability following incubation with different concentrations of meloxicam and/or doxorubicin. (A) CF41.Mg and (B) MDCK cells were incubated 
for 24 and 48 h with meloxicam (0‑25 µg/ml). The percentage of viable cells was determined by MTS assay. Control cells were treated with DMSO alone. 
(C) Viability of CF41.Mg cells incubated for 24 and 48 h with meloxicam (0‑25 µg/ml) and 500 ng/ml doxorubicin. (D) CF41.Mg cells were incubated 
with meloxicam (0‑1 µg/ml) and 24 h later 500 ng/ml doxorubicin was added. Cell viability was measured at 24 and 48 h. Values are presented as the 
mean ± standard deviation of ≥3 independent experiments performed in triplicate. *P<0.05.
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Figure 3. Meloxicam (0.25 µg/ml) has no effect on CF41.Mg cell apoptosis. Doxorubicin alone (500 ng/ml) was used as a positive control. A total of 3 inde-
pendent experiments were performed and values are presented as the mean ± standard deviation. Flow cytometry plots and analysis of the data are illustrated. 
*P<0.05 vs. the control group.
Figure 4. Meloxicam (0.25 µg/ml) decreases the migration of CF41.Mg cells. Incubation with 0.25 µg/ml meloxicam for 24 and 48 h inhibited the migra-
tion of cells compared with the DMSO‑treated control cells in a wound healing assay. A total of 6 repeats were performed and results are presented as the 
mean ± standard deviation. Representative images of the wound healing assay and quantification if the results are presented. Scale bar, 90 µm. *P<0.05 vs. the 
control group.
ITURRIAGA et al:  MELOXICAM REDUCES THE INVASIVENESS OF CF41.Mg CELLS 2203
invasion-promoting molecules in response to meloxicam was 
investigated. The release of MMP-2 and -9 into the culture 
medium was detected through their gelatinase activity by 
gelatin zymography. This was detected in the presence 
and absence of meloxicam. As illustrated in Fig. 6A, only 
MMP-2 activity was detected in the supernatants studied. 
Meloxicam reduced MMP-2 gelatinase activity at 24 and 
48 h, where a stronger intensity of gelatinolytic band was 
observed in absence of meloxicam. Because this measure-
ment of activity cannot be objectively quantifiable, these 
Figure 5. Meloxicam (0.25 µg/ml) decreases the invasion of CF41.Mg cells. The invasive cells were counted in 3 independent Matrigel invasion experiments 
and the results are presented as the mean number of invading cells ± standard deviation. Representative microphotographs and a graph of the results are 
presented. Scale bar, 64 µm. *P<0.05 vs. the control group.
Figure 6. Meloxicam (0.25 µg/ml) increases the activity and expression of MMP‑2 in CF41.Mg cells. (A) Representative gelatin zymography image of MMP‑2 
and 9. (B) Representative Western blot and respective histogram showing the expression of MMP‑2. Values are expressed as mean ± SD and at least three 
independent experiments were performed. *P<0.05 vs. the control group. M24, meloxicam treatment for 24 h; M48, meloxicam treatment for 48 h.
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results were confirmed through western blotting, where 
meloxicam induced a significant decrease in the expression 
of MMP-2 at 48 h (P=0.013; Fig. 6B).
Meloxicam increases β‑catenin phophorylation in CF41.Mg 
cells. The association between meloxicam and the COX-2 
signaling pathway was investigated. A functional interaction 
between COX-2 and β-catenin has been suggested in certain 
types of cancer, where MMPs could act as mediators (6,17). 
Therefore, the levels of total and p forms of β-catenin in 
response to meloxicam were analyzed. A significantly lower 
expression of total β-catenin was observed in CF41.Mg cells 
incubated with meloxicam for 24 and 48 h compared with 
the control group (P<0.0001 and P=0.014, respectively; 
Fig. 7A). In addition, an increased expression of p‑β-catenin 
was detected in CF41.Mg cells incubated with meloxicam 
for 24 h (P=0.074), which was significant at 48 h (P=0.009; 
Fig. 7B).
Meloxicam does not affect COX‑2 expression in CF41.Mg 
cells. To evaluate whether meloxicam affects COX-2 expres-
sion in CF41.Mg cells, COX-2 protein levels in the absence 
and presence of 0.25 µg/ml of meloxicam, at 24 and 48 h, 
were compared. No significant difference in the expression 
of COX-2 was observed between any of the groups (Fig. 8). 
The amount of PGE2 in supernatants could not be determined, 
since all values were out of the curve provided by the ELISA 
kit, being too low to be detected by this method.
Discussion
Several previous studies have proposed that NSAIDs could 
be used as an anticancer drug or as part of a chemopreventive 
therapy. Zhong et al (32) recently suggested that the long-term 
use of aspirin may reduce the risk of breast cancer in humans. 
In veterinary medicine, a number of previous studies have 
evaluated the in vitro and in vivo effects of different NSAIDs 
on animal tumors, including canine mammary tumors. For 
example, etodolac, meloxicam and celecoxib have been 
identified to suppress canine mammary tumor cell growth 
in vitro (24). By contrast, piroxicam, a non‑selective NSAID, has 
been demonstrated to trigger clinical partial remissions in dogs 
with mammary carcinoma (33,34). Meloxicam is licensed for 
veterinary use and is widely utilized in the management of pain 
and inflammatory diseases; it is a potent NSAID of the enolic 
acid class of oxicam derivatives, which has exhibited a prefer-
ence for COX-2 compared with COX-1 inhibition at therapeutic 
concentrations (21,36). Due to its preferential COX‑2 inhibitory 
capacity, meloxicam has a better gastric and renal safety profile 
compared with non‑selective NSAIDs (21,35,36).
Since COX-2 is associated with poor cancer prognosis, the 
antitumor effect of meloxicam has been studied in different 
canine tumor cells. Several previous studies have demon-
strated that meloxicam induces a reduction in cell proliferation 
and/or increase in apoptosis at high concentrations, exceeding 
the physiological maximum serum levels (23,24). For example, 
in canine mammary tumor cells, 100 µM meloxicam was 
demonstrated to inhibit cell proliferation, but not induce 
Figure 7. Meloxicam (0.25 µg/ml) increases β‑catenin expression in CF41.Mg cells. Representative western blots and quantification of (A) total β-catenin and 
(B) p‑β‑catenin. Values are presented as the mean ± standard deviation of ≥3 independent experiments. *P<0.05 vs. the control group. p, phosphorylated; M24, 
meloxicam treatment for 24 h; M48, meloxicam treatment for 48 h.
Figure 8. Meloxicam (0.25 µg/ml) does not affect COX-2 expression in 
CF41.Mg cells. (A) Representative western blots showing the expression of 
COX‑2 in CF41.Mg cells for 24 (left blot) and 48 h (right blot) and (B) quan-
tification of COX‑2 expression. Values are presented as the mean ± standard 
deviation of 3 independent experiments.
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apoptosis (24). By contrast, Knottenbelt et al (23) revealed that 
meloxicam (10-160 µg/ml) induced inhibition of cell prolif-
eration and an increase in apoptosis in mammary carcinoma 
cells in a dose-dependent manner, with maximum inhibition 
observed at a dose of 160 µg/ml.
Metastatic cancer cells exhibit high motility, typically 
observed when cell-cell adhesions are lost and resulting in 
increased invasiveness (4). Since CF41.Mg cells exhibit a 
mesenchymal phenotype with characteristic low expression of 
E-cadherin (25), they were used as an in vitro model to study 
the invasive potential of canine mammary carcinoma cells in 
the present study. In this the present study, meloxicam had no 
effect on proliferation or apoptosis. However, a lower dose of 
meloxicam was used in the present study in order to mimic the 
plasma concentration observed in dogs receiving the routinely 
therapeutic dose of 0.1 mg/kg (35). In addition, meloxicam 
was not demonstrated to augment the cytotoxic effect of doxo-
rubicin, a chemotherapy drug frequently used as an adjuvant 
treatment in dogs with mammary carcinoma.
Notably, a low concentration of meloxicam (0.25 µg/ml) 
was identified to significantly inhibit CF41.Mg cell migra-
tion and invasion in the present study. These results may be 
mechanistically associated with the reduced expression/
activity of MMP‑2 observed. In accordance with these results, 
Larkins et al (37) demonstrated that various COX-2 inhibitors 
reduce motility, invasion and MMP expression in breast cancer 
cells. This group also reported a decreased MMP-2 expres-
sion with undetectable levels of pro- and active MMP-9 under 
basal conditions, similar to the observations of the present 
study. These results suggest that MMP-9 does not effect on the 
invasiveness of CF41.Mg cells, while MMP-2 does.
In the current study, exposure to meloxicam reduced total 
β-catenin expression while increasing its phosphorylation. 
These effects may induce the destabilization and degradation 
of β-catenin via the proteasome, resulting in less β-catenin 
available for nuclear translocation and transcription of target 
genes, as described by Hugo et al (6). Thus, it can be suggested 
that the anti-invasive effect of meloxicam on CF41.Mg cells is 
associated with enhanced β-catenin degradation.
No significant differences in the levels of COX-2 in 
response to 0.25 µg/ml meloxicam treated were observed 
in the present study, which is concordant with the results of 
previous studies (24,38). This indicates that meloxicam does 
not alter COX-2 expression; however, it does not exclude its 
participation in regulating the activity of COX-2.
It was expected that PGE2, a product of COX‑2 activity, 
would be reduced in a dose-dependent manner following 
meloxicam treatment. However, PGE2 was not detected under 
the experimental conditions of the present study. A previous 
report of COX-2 expression and activity in CF41.Mg cells 
identified no production of PGE2, which is consistent with 
our results (39). In this regard, it has been suggested that the 
rapid metabolic inactivation of PGE2 in cancer cells may limit 
its detection (40), explaining these outcomes. Unfortunately, 
these findings prevent the determination of whether the effects 
of meloxicam are dependent on COX-2 activity.
The PG signaling pathway is not the only mechanism 
of detecting inhibitory activity associated with meloxicam 
and other NSAIDs, as the antiproliferative effects were 
observed also in COX-negative cells lines (41). Several 
inhibitors of COX‑2 have been identified to inhibit carbonic 
anhydrase (42), which is associated with tumor malignancy 
in breast cancer (43). This potential association should be 
explored in future studies to elucidate the COX-2-independent 
anti-invasive effects of meloxicam on CF41.Mg cells. There 
are numerous COX inhibitors available and it is necessary to 
extend these observations by analyzing their potential effect 
on the metastatic behavior of canine mammary tumor cells at 
in vivo concentrations.
In conclusion, the results of the present study demonstrate 
that meloxicam has no effect on the proliferation or apoptosis 
of CF41.Mg cells. In addition, the present study identified 
that meloxicam while significantly reduces CF41.Mg cell 
invasion, at least in part by decreasing MMP-2 secretion and 
enhancing the degradation of β-catenin. Thus, meloxicam at 
low concentration of 0.25 µg/ml, has an anti-invasive effect in 
canine mammary carcinoma cells, suggesting that meloxicam 
has a potential adjunctive therapeutic application, which could 
be useful in controlling the invasion and metastasis of canine 
mammary carcinomas.
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